Vaccines,
Год журнала:
2024,
Номер
12(9), С. 1071 - 1071
Опубликована: Сен. 19, 2024
Foot-and-mouth
disease
(FMD)
is
globally
recognized
as
a
highly
economically
devastating
and
prioritized
viral
affecting
livestock.
Vaccination
remains
crucial
preventive
measure
against
FMD.
The
improvement
of
current
vaccine
platforms
could
help
control
outbreaks,
leading
to
the
potential
eradication
disease.
In
this
review,
we
describe
variances
in
virulence
immune
responses
among
FMD-susceptible
host
species,
specifically
bovines
pigs,
highlighting
details
host–pathogen
interactions
their
impact
on
severity
This
knowledge
serves
an
important
foundation
for
translating
our
insights
into
rational
design
vaccines
countermeasure
strategies,
including
use
interferon
biotherapeutic
agent.
Ultimately,
aim
bridge
gap
between
understanding
FMDV
biology
practical
approaches
potentially
eradicate
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Сен. 6, 2023
Since
the
successful
application
of
messenger
RNA
(mRNA)
vaccines
in
preventing
COVID-19,
researchers
have
been
striving
to
develop
mRNA
for
clinical
use,
including
those
exploited
anti-tumor
therapy.
cancer
emerged
as
a
promising
novel
approach
immunotherapy,
offering
high
specificity,
better
efficacy,
and
fewer
side
effects
compared
traditional
treatments.
Multiple
therapeutic
are
being
evaluated
preclinical
trials,
with
early-phase
results.
However,
development
these
faces
various
challenges,
such
tumor
heterogeneity,
an
immunosuppressive
microenvironment,
practical
obstacles
like
vaccine
administration
methods
evaluation
systems
application.
To
address
we
highlight
recent
advances
from
studies
trials
that
provide
insight
into
identifying
associated
discuss
potential
strategies
overcome
them.
In
future,
it
is
crucial
caution
diligence
while
promoting
innovation
existing
barriers.
A
delicate
balance
between
opportunities
challenges
will
help
guide
progress
this
field
towards
its
full
potential.
Journal of Medical Virology,
Год журнала:
2023,
Номер
95(2)
Опубликована: Фев. 1, 2023
Abstract
Messenger
RNA
(mRNA)
vaccines
against
COVID‐19
are
the
first
authorized
biological
preparations
developed
using
this
platform.
During
pandemic,
their
administration
has
been
proven
to
be
a
life‐saving
intervention.
Here,
we
review
main
advantages
of
mRNA
vaccines,
identify
further
technological
challenges
met
during
development
platform,
and
provide
an
update
on
clinical
progress
leading
vaccine
candidates
different
viruses
that
include
influenza
viruses,
human
immunodeficiency
virus
1,
respiratory
syncytial
virus,
Nipah
Zika
cytomegalovirus,
Epstein‐Barr
virus.
The
prospects
manufacturing
in
low‐income
countries
also
discussed.
ongoing
interest
research
technology
likely
overcome
some
existing
for
(e.g.,
related
storage
conditions
immunogenicity
components
lipid
nanoparticles)
enhance
portfolio
diseases
which
classical
formulations
already
authorized.
It
may
open
novel
pathways
protection
infections
consequences
no
safe
efficient
immunization
methods
currently
available.
Nature Communications,
Год журнала:
2023,
Номер
14(1)
Опубликована: Дек. 5, 2023
Abstract
The
respiratory
system,
especially
the
lung,
is
key
site
of
pathological
injury
induced
by
SARS-CoV-2
infection.
Given
low
feasibility
targeted
delivery
antibodies
into
lungs
intravenous
administration
and
short
half-life
period
in
intranasal
or
aerosolized
immunization,
mRNA
encoding
broadly
neutralizing
with
lung-targeting
capability
can
perfectly
provide
high-titer
to
prevent
Here,
we
firstly
identify
a
human
monoclonal
antibody,
8-9D,
broad
potency
against
variants.
neutralization
mechanism
this
antibody
explained
structural
characteristics
8-9D
Fabs
complex
Omicron
BA.5
spike.
In
addition,
evaluate
efficacy
using
safe
robust
platform
compare
performance
when
its
not
selectively
delivered
lungs.
lung-selective
enables
expression
which
blocks
invasion
virus,
thus
effectively
protecting
female
K18-hACE2
transgenic
mice
from
challenge
Beta
BA.1
variant.
Our
work
underscores
potential
application
prevention
treatment
infections
caused
circulating
Microorganisms,
Год журнала:
2025,
Номер
13(2), С. 380 - 380
Опубликована: Фев. 9, 2025
Rabies
is
a
fatal
zoonotic
disease
and
causes
about
59,000
human
deaths
globally
every
year.
Especially,
its
mortality
almost
100%
in
cases
where
the
rabies
virus
has
transmitted
to
central
nervous
system.
The
special
life
cycle
pathogenic
mechanism
make
it
difficult
for
host
immune
system
combat
viruses.
Vaccination
including
pre-exposure
post-exposure
prophylaxis
an
effective
strategy
prevention.
vaccination
mainly
applied
animals
most
application
humans.
Although
vaccines
are
widely
used
seem
be
safe
effective,
there
some
disadvantages,
limitations,
or
challenges
affecting
vaccine
promotion
distribution.
Therefore,
more
convenient,
safer,
cheaper
have
been
developed
being
developed.
development
of
novel
focusing
on
based
purified
Vero
cell-cultured
freeze-dried
(PVRV).
PVRV
demonstrated
promising
secure
animal
studies
clinical
trials.
Moreover,
mRNA-based
shown
potential
enhance
safety
efficacy
both
uses.
Journal of Medical Virology,
Год журнала:
2025,
Номер
97(2)
Опубликована: Фев. 1, 2025
ABSTRACT
The
term
“Disease
X”,
first
introduced
by
the
World
Health
Organization
(WHO)
in
2018,
symbolizes
threat
of
an
unknown
pathogen
capable
causing
a
global
pandemic.
Classified
as
“priority
pathogens,”
Disease
X
stands
alongside
well‐known
threats
like
SARS,
Ebola,
and
ZIKV
due
to
its
potential
for
widespread
outbreaks.
SARS‐CoV‐2
is
considered
X”
fulfill
this
prediction,
demonstrating
devastating
impact
such
pathogens
can
have.
A
future
could
pose
even
greater
threat,
with
catastrophic
consequences.
This
paper
examines
origins
pathogens,
drawing
lessons
from
outbreaks
MERS,
SARS‐CoV‐2.
It
also
highlights
strategic
approaches
detect,
prevent,
respond
effectively
mitigate
risk
pandemics.
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Март 4, 2025
mRNA
vaccines
utilize
single-stranded
linear
DNA
as
a
template
for
in
vitro
transcription.
The
is
introduced
into
the
cytoplasm
via
corresponding
delivery
system
to
express
target
protein,
which
then
performs
its
relevant
biological
function.
are
beneficial
various
fields,
including
cancer
vaccines,
infectious
disease
protein
replacement
therapy,
and
treatment
of
rare
diseases.
They
offer
advantages
such
simple
manufacturing
process,
quick
development
cycle,
ease
industrialization.
Additionally,
afford
flexibility
adjusting
antigen
designs
combining
sequences
multiple
variants,
thereby
addressing
issue
frequent
mutations
pathogenic
microorganisms.
This
paper
aims
provide
an
extensive
review
global
current
research
status
with
focus
on
immunogenicity,
classification,
design,
vector
development,
stability,
biomedical
application.
Moreover,
study
highlights
challenges
offers
insights
future
directions
development.
J — Multidisciplinary Scientific Journal,
Год журнала:
2023,
Номер
6(2), С. 220 - 235
Опубликована: Апрель 17, 2023
Pharmacovigilance
databases
are
showing
evidence
of
injury
in
the
context
modified
COVID-19
mRNA
products.
According
to
recent
publications,
adverse
event
reports
linked
injections
largely
point
spike
protein
as
an
aetiological
agent
events,
but
we
propose
that
platform
itself
may
be
culpable.
To
assess
safety
current
and
future
vaccines,
further
analysis
is
needed
on
risks
due
itself,
not
specifically
expressed
antigen.
If
harm
can
exclusively
conclusively
attributed
protein,
then
it
possible
vaccines
expressing
other
antigens
will
safe.
harms
attributable
regardless
toxicity,
or
lack
thereof,
antigen
expressed,
inherently
unsafe,
pending
modification.
In
this
work,
examine
previous
studies
RNA-based
delivery
by
a
lipid
nanoparticle
(LNP)
break
down
elements
harm.
Vaccines,
Год журнала:
2023,
Номер
11(9), С. 1502 - 1502
Опубликована: Сен. 19, 2023
The
COVID-19
pandemic
has
been
met
with
an
unprecedented
response
from
the
scientific
community,
leading
to
development,
investigation,
and
authorization
of
vaccines
antivirals,
ultimately
reducing
impact
SARS-CoV-2
on
global
public
health.
However,
is
far
being
eradicated,
continues
evolve,
causes
substantial
health
economic
burdens.
In
this
narrative
review,
we
posit
essential
points
its
responsible
management
during
transition
acute
phase
pandemic.
As
discussed,
despite
Omicron
(sub)variant(s)
causing
clinically
milder
infections,
a
negligible
pathogen.
It
requires
continued
genomic
surveillance,
particularly
if
one
considers
that
future
(sub)lineages
do
not
necessarily
have
be
milder.
Antivirals
remain
elements
in
management.
former
could
benefit
further
development
improvements
dosing,
while
seasonal
administration
latter
simplification
increase
interest
tackle
vaccine
hesitancy.
also
ensure
accessibility
pharmaceuticals
low-income
countries
improve
understanding
their
use
context
long-term
goals
Regardless
location,
primary
role
awareness
education
must
played
by
healthcare
workers,
who
directly
communicate
patients
serve
as
models
for
healthy
behaviors.
Biomolecules,
Год журнала:
2024,
Номер
14(4), С. 503 - 503
Опубликована: Апрель 21, 2024
Cancer
remains
one
of
the
global
leading
causes
death
and
various
vaccines
have
been
developed
over
years
against
it,
including
cell-based,
nucleic
acid-based,
viral-based
cancer
vaccines.
Although
many
effective
in
vivo
clinical
studies
some
FDA-approved,
there
are
major
limitations
to
overcome:
(1)
developing
universal
vaccine
for
a
specific
is
difficult,
as
tumors
with
different
antigens
individuals,
(2)
tumor
may
be
similar
body’s
own
antigens,
(3)
possibility
recurrence.
Therefore,
personalized
ability
distinguish
between
indispensable.
This
paper
provides
comprehensive
review
types
highlights
important
factors
necessary
efficient
Moreover,
application
other
technologies
therapy
discussed.
Finally,
several
insights
conclusions
presented,
such
using
cold
plasma
stem
cells
future
vaccines,
tackle
developmental
process.